Carlos A. Cardenas
Rare Ovarian Tumors (ROT) often linger in the shadows of the oncology world, individually rare but collectively impactful. As I delve into this fascinating subject, my goal is to offer fresh insights into the remarkable progress made, thanks to collaborative networks, refined classifications, and cutting-edge clinical trials.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu